152 related articles for article (PubMed ID: 35146837)
61. Candida colonization and candiduria in critically ill patients in the intensive care unit.
Viale P
Drugs; 2009; 69 Suppl 1():51-7. PubMed ID: 19877735
[TBL] [Abstract][Full Text] [Related]
62. Breakthrough Candidemia In Children On Micafungin.
Funaki T; Miyairi I
Pediatr Infect Dis J; 2018 Dec; 37(12):1258-1260. PubMed ID: 29570179
[TBL] [Abstract][Full Text] [Related]
63. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.
Steinbach WJ; Roilides E; Berman D; Hoffman JA; Groll AH; Bin-Hussain I; Palazzi DL; Castagnola E; Halasa N; Velegraki A; Dvorak CC; Charkabarti A; Sung L; Danziger-Isakov L; Lachenauer C; Arrieta A; Knapp K; Abzug MJ; Ziebold C; Lehrnbecher T; Klingspor L; Warris A; Leckerman K; Martling T; Walsh TJ; Benjamin DK; Zaoutis TE;
Pediatr Infect Dis J; 2012 Dec; 31(12):1252-7. PubMed ID: 22982980
[TBL] [Abstract][Full Text] [Related]
64. Antifungal susceptibilities of Candida species isolated from urine culture.
Toka Özer T; Durmaz S; Yula E
J Infect Chemother; 2016 Sep; 22(9):629-32. PubMed ID: 27452427
[TBL] [Abstract][Full Text] [Related]
65. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
66. Epidemiologic and microbiologic evaluation of nosocomial infections associated with Candida spp in children: A multicenter study from Istanbul, Turkey.
Sutcu M; Salman N; Akturk H; Dalgıc N; Turel O; Kuzdan C; Kadayifci EK; Sener D; Karbuz A; Erturan Z; Somer A
Am J Infect Control; 2016 Oct; 44(10):1139-1143. PubMed ID: 27339794
[TBL] [Abstract][Full Text] [Related]
67. [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients].
Pozo-Laderas JC
Rev Iberoam Micol; 2009 Mar; 26(1):69-74. PubMed ID: 19463281
[TBL] [Abstract][Full Text] [Related]
68. Comparison of Amphotericin B Bladder Irrigations Versus Fluconazole for the Treatment of Candiduria in Intensive Care Unit Patients.
Sullivan KA; Caylor MM; Lin FC; Campbell-Bright S
J Pharm Pract; 2017 Jun; 30(3):347-352. PubMed ID: 27112735
[TBL] [Abstract][Full Text] [Related]
69. The outcome of candiduria in pediatric patients.
Chun CS; Turner RB
Diagn Microbiol Infect Dis; 1991; 14(2):119-23. PubMed ID: 1873970
[TBL] [Abstract][Full Text] [Related]
70. Candida urinary tract infections--treatment.
Fisher JF; Sobel JD; Kauffman CA; Newman CA
Clin Infect Dis; 2011 May; 52 Suppl 6():S457-66. PubMed ID: 21498839
[TBL] [Abstract][Full Text] [Related]
71. [Antifungal activity and clinical efficacy of micafungin sodium (Funguard)].
Ikeda F
Nihon Yakurigaku Zasshi; 2003 Oct; 122(4):339-44. PubMed ID: 14501170
[TBL] [Abstract][Full Text] [Related]
72. Micafungin - the newest echinocandin.
Temesgen Z; Barreto J; Vento S
Drugs Today (Barc); 2009 Jun; 45(6):469-78. PubMed ID: 19856528
[TBL] [Abstract][Full Text] [Related]
73. Ultrasonographic evaluation of the children with candiduria for the fungal ball: Is It necessary?
Devrim F; Besin D; Colak R; Kantar A; Sorguc Y; Gülfidan G; Dincel N; Oral A; Calkavur S; Ağın H; Hosgör M; Bayram N; Devrim İ
J Pediatr Urol; 2021 Oct; 17(5):738.e1-738.e5. PubMed ID: 34389232
[TBL] [Abstract][Full Text] [Related]
74. Risk factors for isolation of fluconazole and echinocandin non-susceptible
Papadimitriou-Olivgeris M; Spiliopoulou A; Fligou F; Tsiata E; Kolonitsiou F; Nikolopoulou A; Papamichail C; Spiliopoulou I; Marangos M; Christofidou M
J Med Microbiol; 2021 Aug; 70(8):. PubMed ID: 34431765
[No Abstract] [Full Text] [Related]
75. Micafungin: a new echinocandin antifungal.
Joseph JM; Jain R; Danziger LH
Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
[TBL] [Abstract][Full Text] [Related]
76. Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.
Vehreschild JJ; Cornely OA
Future Microbiol; 2006 Aug; 1(2):161-70. PubMed ID: 17661660
[TBL] [Abstract][Full Text] [Related]
77. Invasive candidiasis in pediatric intensive care in Greece: a nationwide study.
Vogiatzi L; Ilia S; Sideri G; Vagelakoudi E; Vassilopoulou M; Sdougka M; Briassoulis G; Papadatos I; Kalabalikis P; Sianidou L; Roilides E
Intensive Care Med; 2013 Dec; 39(12):2188-95. PubMed ID: 23942859
[TBL] [Abstract][Full Text] [Related]
78. Management of candiduria in hospitalized patients: a single-center study on the implementation of IDSA guidelines and factors affecting clinical decisions.
He Z; Huo X; Lei D; Zhao H; Jia K; Wang F
Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):59-65. PubMed ID: 32734337
[TBL] [Abstract][Full Text] [Related]
79. Population Pharmacokinetic Model and Optimal Sampling Strategies for Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Zijlstra JG; van der Werf TS; Alffenaar JWC; Touw DJ
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0111322. PubMed ID: 36377940
[No Abstract] [Full Text] [Related]
80. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
